8-K: Oncocyte Secures $10.2 Million in Private Placement, Expands Transplant Testing Reach

Oncocyte Corporation has successfully raised $10.2 million through a private placement to advance its organ transplant testing and general corporate activities.

Summary

• Oncocyte Corporation has entered into a securities purchase agreement for a private placement, raising approximately $10.2 million before fees and expenses.
• The private placement involves the sale of 3,461,138 shares of common stock at $2.948 per share.
• Certain company insiders participated, purchasing 37,037 shares at $2.970 per share.
• The company intends to use the net proceeds for general corporate purposes and working capital.
• The closing of the private placement is expected on or about October 4, 2024.
• Oncocyte has also entered into a registration rights agreement, requiring them to file a registration statement for the resale of these shares within 15 days and to have it declared effective within 30 to 45 days.
• The company's new customers include two leading transplant university hospitals in the U.S. and Germany, who will use the GraftAssure research assay.
• Oncocyte has submitted a plan for an in-vitro diagnostic (IVD) version of its dd-cfDNA kitted test to the FDA, with a meeting scheduled for early December.

Sentiment

Score: 8

Explanation: The document conveys a positive sentiment due to the successful capital raise, adoption of their technology by major institutions, and progress with FDA submissions. The company is executing on its strategy and has strong support from investors and partners.

Positives

• The successful private placement provides significant funding for working capital and general corporate purposes.
• The adoption of GraftAssure by two major transplant centers validates the company's technology and market strategy.
• The submission of the IVD plan to the FDA is a key step towards commercializing a clinical product.
• The partnership with Bio-Rad Laboratories provides a strong foundation for global expansion.
• The company is experiencing strong interest in its transplant assay, exceeding management's expectations.

Negatives

• The private placement results in dilution of existing shares.
• The company is still in the research-use-only phase for GraftAssure, and clinical adoption is dependent on FDA clearance.
• The company is reliant on third-party suppliers for its blood sample analytic system.

Risks

• The company faces risks inherent in the development and commercialization of diagnostic tests.
• There is uncertainty in the results of clinical trials and regulatory approvals.
• The company may experience interruptions to supply chains.
• The company needs to obtain future capital to continue operations.
• The company must maintain intellectual property rights in all applicable jurisdictions.
• The company has obligations to third parties with respect to licensed or acquired technology and products.
• The company needs to obtain third-party reimbursement for patients' use of any diagnostic tests.
• The company faces risks inherent in strategic transactions, such as the potential failure to realize anticipated benefits.

Future Outlook

Oncocyte plans to continue expanding its customer base, particularly in major transplant centers, and to advance its clinical product development with the FDA. The company aims to capture a significant share of the estimated $1 billion transplant market.

Management Comments

• We are thrilled with the market response to GraftAssure.
• We believe these institutions share our vision of democratizing access to this molecular diagnostic technology.
• This funding helps us to continue delivering on the promise that we made to expand access to organ transplant rejection testing globally.
• We are grateful for the support of our current and new shareholders who share our vision of democratizing access for transplant patients, transplant centers, and transplant researchers around the world.
• Our team remains committed to executing on our strategy and creating shareholder value.
• This offering reflects growing confidence in our business opportunity and the market potential we are addressing.

Industry Context

The announcement highlights Oncocyte's efforts to establish itself in the concentrated transplant market, where a small number of academic centers account for a large portion of transplant volumes. The partnership with Bio-Rad leverages their global infrastructure to reach these key centers.

Comparison to Industry Standards

• The private placement is a common method for biotech companies to raise capital, especially those in the development stage.
• The adoption of GraftAssure by leading transplant centers is a positive sign, as these institutions are often early adopters of new technologies.
• The submission of an IVD plan to the FDA is a standard step for companies seeking to commercialize clinical diagnostic tests.
• The partnership with Bio-Rad is similar to other strategic alliances in the diagnostics industry, where larger companies provide distribution and commercialization support.
• The company's focus on the concentrated transplant market is a common strategy for companies in this space, as it allows for targeted sales and marketing efforts.

Related Party Transactions

• Certain insiders of the company subscribed for 37,037 of the shares of common stock sold in the private placement, at a purchase price of $2.970 per share of common stock.

Stakeholder Impact

• Shareholders will experience dilution due to the issuance of new shares.
• Employees will benefit from the company's increased financial stability and growth prospects.
• Customers (transplant centers) will gain access to new diagnostic tools.
• Strategic partners like Bio-Rad will benefit from the company's growth and market expansion.
• Creditors will have increased confidence in the company's ability to meet its obligations.

Next Steps

• The company will close the private placement on or about October 4, 2024.
• Oncocyte will file a registration statement for the resale of the shares within 15 days.
• The company will seek to have the registration statement declared effective within 30 to 45 days.
• Oncocyte will continue to work with transplant centers to adopt GraftAssure.
• The company will meet with the FDA in early December to discuss the IVD submission.
• Oncocyte plans to begin the validation process for the IVD test in early 2025.

Key Dates

Keywords

private placement, organ transplant, GraftAssure, dd-cfDNA, FDA, IVD, Bio-Rad Laboratories, molecular diagnostics, transplant centers, registration rights